Section Arrow
PHVS.NASDAQ
- Pharvaris NV
Quotes are at least 15-min delayed:2026/11/04 14:31 EST
Regular Hours
Last
 34.16
-0.62 (-1.78%)
Day High 
35.415 
Prev. Close
34.78 
1-M High
35.3 
Volume 
172.59K 
Bid
34.09
Ask
34.24
Day Low
33.03 
Open
35.06 
1-M Low
27.68 
Market Cap 
2.44B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 32.45 
20-SMA 31.37 
50-SMA 33.56 
52-W High 43.25 
52-W Low 21.21 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.60/-2.88
Enterprise Value
2.44B
Balance Sheet
Book Value Per Share
4.78
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CRISCuris Inc.1.2301+0.5162+72.31%0.2PE
KPTIKaryopharm Therapeutics Inc.0.0852-0.0031-3.51%-- 
GERNGeron Corp1.035+0.105+11.29%-- 
INOInovio Pharmaceuticals1.655-0.005-0.30%-- 
NRIXNurix Therapeutics16.31-9.51-36.83%10.63PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel smallmolecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.